Here's some stats from a recent Thomson Reuters analysis of the pharma industry with respect to R&D spending and new drugs in the pipeline. The study shows Big Pharma put the clamps on R&D spending while sharply reducing the number of new phase I and II trials and putting the brakes on phase III trials.
Doing Deals With Biotechs Fails To Yield Results? // Pharmalot.
The report shows that Big Pharma stopped 55 phase III trials in the past 3 years and that was 2x as many as had been terminated in the three previous years. Additionally, phase I studies dropped by 47%, phase II studies by 53% and the number of new drugs entering phase III dropped by 55%.
High failure rates, compounded by a big decrease in new NMEs, is a great concern to the industry. Only 21 NMEs were launched worldwide in 2010 and that followed only 26 the previous year. This is the lowest number in a decade. It appears that the strategy of in-licensing more drugs for development is not yet paying off. See Fierce Biotech.
Posted by Bruce Lehr June 27th 2011.
Comments